Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.

Breast cancer research and treatment - 1 Nov 2024

Wang Zheng, Lu Yujie, Han Mengyuan, Li Anqi, Ruan Miao, Tong Yiwei, Yang Cuiyan, Zhang Xiaotian, Zhu Changbin, Wang Chaofu, Shen Kunwei, Dong Lei, Chen Xiaosong

Abstract excerpt

BACKGROUND: The aim of this study was to assess homologous recombination deficiency (HRD) status and its correlation with carboplatin treatment response in early triple-negative breast cancer (TNBC) patients. METHODS: Tumor tissues from 225 consecutive TNBC patients were evaluated with an HRD panel and homologous recombination-related (HRR) gene expression data. HRD positivity was defined as a high HRD score...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carboplatin

Share to Homologous Recombination

Share to Neoadjuvant Therapy

Share to Neoplasm Staging

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39048852
DOI: 10.1007/s10549-024-07436-1
PMCID: PMC11457550

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.PMID 39048852Read ↗

Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.Semantic proximity Read ↗

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancerSemantic proximity Read ↗

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Semantic proximity Read ↗

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.Semantic proximity Read ↗

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair DeficiencySemantic proximity Read ↗

Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.Semantic proximity Read ↗

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancerSemantic proximity Read ↗

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.Semantic proximity Read ↗

AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in ChinaSemantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialSemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.